Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States

Objective The introduction of biosimilars for rheumatologic diseases (RDs) has provided a potentially lower‐cost therapy compared with their bio‐originator products; however, adoption of biosimilars may be challenged by patient perceptions. The objective of this study was to describe patients’ perspectives of switching from infliximab to infliximab‐dyyb.